Loading data for IMRN — first visit, this takes a few seconds.
Immuron Limited (IMRN)
NasdaqCM: IMRN
· Real-Time Price · USD
1.12
-0.06 (-5.08%)
At close: Aug 21, 2026, 8:00 PM
1.14
+1.38%
After-hours: 6:14 PM
The price, the headline numbers and the latest news, in one place.
Immuron Limited (IMRN) Stock Price, Analysis & Data
-5.08% (1D)
No data available
| Bid | 1.13 |
| Market Cap | 9.04M |
| Revenue (ttm) | 7.48M |
| Net Income (ttm) | -4.65M |
| 0.51 | |
| -0.53 | |
| n/a | |
| -112 | |
| P/B (ttm) | 0.99 |
| P/S (ttm) | 1.21 |
| Earnings Date | Feb 26, 2019 |
| Ask | 1.2 |
| Volume | 7,263 |
| Avg. Volume (20D) | 240,879 |
| Open | 1.17 |
| Previous Close | 1.18 |
| Day's Range | 1.12 - 1.18 |
| 52-Week Range | 0.68 - 2.39 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMRN
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for diges...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 9, 2017
Employees 7
Stock Exchange NasdaqCM
Ticker Symbol IMRN
Website https://www.immuron.com.au
Financial Performance
In 2025, Immuron's revenue was 7.29M, an increase of 48.63% compared to the previous year's 4.9M. Earnings were -5.22M, a decrease of -24.81%.
Financial StatementsImmuron Limited is scheduled to release its earnings on Feb 26, 2019, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
